Glycogen storage disease type III natural history, complications and prognosis
Glycogen storage disease type III Microchapters |
Differentiating Glycogen storage disease type III from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type III natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type III natural history, complications and prognosis |
FDA on Glycogen storage disease type III natural history, complications and prognosis |
CDC on Glycogen storage disease type III natural history, complications and prognosis |
Glycogen storage disease type III natural history, complications and prognosis in the news |
Blogs on Glycogen storage disease type III natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of glycogen storage disease type III include:[1][2][3][4]
- Left ventricular hypertrophy
- Cardiomyopathy
- [Complication 3]
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
- Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Lee P, Burch M, Leonard JV (1995). "Plasma creatine kinase and cardiomyopathy in glycogen storage disease type III". J Inherit Metab Dis. 18 (6): 751–2. PMID 8750616.
- ↑ Labrune P, Huguet P, Odievre M (1991). "Cardiomyopathy in glycogen-storage disease type III: clinical and echographic study of 18 patients". Pediatr Cardiol. 12 (3): 161–3. doi:10.1007/BF02238523. PMID 1876514.
- ↑ Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT (1992). "Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy". Ann Intern Med. 116 (11): 896–900. PMID 1580445.
- ↑ Talente GM, Coleman RA, Alter C, Baker L, Brown BI, Cannon RA; et al. (1994). "Glycogen storage disease in adults". Ann Intern Med. 120 (3): 218–26. PMID 8273986.